Emanuel, EJ, Miller, FG. The ethics of placebo-controlled trials – a middle ground. N Eng J Med
2001; 345: 915–9.
Weijer, C. Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?
1999; 35: 211–8.
Temple, R, Ellenberg, SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Ann Intern Med
2000; 133: 455–63.
World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA
2013; 310: 2191–4.
Kim, SYH. Benefits and burdens of placebos in psychiatric research. Psychopharmacology
2003; 171: 13–8.
Khan, A, Warner, HA, Brown, WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials. Arch Gen Psychiatry
2000; 57: 311–7.
Kim, SYH, Holloway, RG. Burdens and benefits of placebos in antidepressant clinical trials: a decision and cost-effectiveness analysis. Am J Psychiatry
2003; 160: 1272–6.
Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Beck, AT, Ward, C, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry
1961; 4: 561–7.
Endicott, J, Lam, RW, Hsu, MA, Fayyad, R, Boucher, M, Guico-Pabia, CJ. Improvements in quality of life with desvenlafaxine 50 mg/d vs placebo in employed adults with major depressive disorder. J Affective Disorders
2014; 166: 307–14.
McGirr, A, Berlim, MT, Bond, DJ, Fleck, MP, Yatham, LN, Lam, RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med
2014: 45: 693–704.
Kennedy, SH, Avedisova, A, Gimenez-Montesinos, N, Belaidi, C, de Bodinat, C, Agomelatine Study Group. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder. Eur Neuropsychopharmacol
2014; 24: 553–63.
Robinson, M, Oakes, TM, Raskin, J, Liu, P, Shoemaker, S, Nelson, JC. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry
2014; 22: 34–45.
Boulenger, JP, Loft, H, Olsen, CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol
2014; 29: 138–49.
Sambunaris, A, Bose, A, Gommoll, CP, Chen, C, Greenberg, WM, Sheehan, DV. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J Clin Psychopharmacol
2014; 34: 47–56.
Leon, AC, Mallinckrodt, CH, Chuang-Stein, C, Archibald, DG, Archer, GE, Chartier, K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry
2006; 59: 1001–5.